Industry News

Join WhatsApp Channel 

GPAT caoching

  • Sun Pharma Advanced Research Company Ltd and Sun Pharmaceutical Industries Ltd. announced a worldwide licensing agreement on the development and commercialization of SCD-044 which is being evaluated as a potential oral treatment for atopic dermatitis, psoriasis and other auto-immune disorders. SCD-044 is entering phase 2 clinical trials.

  • Troikaa Pharmaceuticals receives US patent for Dynapar QPS
    22 May 2020
    Troikaa Pharmaceuticals receives US patent for Dynapar QPS

    Ahmedabad based Troikaa Pharmaceuticals Ltd. has received patent for its novel non-aqueous Topical Solution of Diclofenac by the U.S. Patent Office which is marketed under the brand name Dynapar QPS.

  • US based Sorrento Therapeutics claims breakthrough against COVID-19, shares jumps around 244 percent
    17 May 2020
    US based Sorrento Therapeutics claims breakthrough against COVID-19, shares jumps around 244 percent

    San Diego based Sorrento Therapeutics claims that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration which lead to jumps in stocks around 244%.

  • Pfizer Inc and BioNTech SE announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.

  • Gilead Sciences, Inc. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19, under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and references the Emergency Use Authorization of remdesivir in the United States.

Subscribe to Industry News